![](/img/cover-not-exists.png)
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
Cortés, Javier, Dieras, Véronique, Ro, Jungsil, Barriere, Jérôme, Bachelot, Thomas, Hurvitz, Sara, Le Rhun, Emilie, Espié, Marc, Kim, Sung-Bae, Schneeweiss, Andreas, Sohn, Joo Hyuk, Nabholtz, Jean-MarVolume:
16
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(15)00373-3
Date:
December, 2015
File:
PDF, 384 KB
english, 2015